NO943101L - 2,6-methano-2H-quinolizine derivative as a 5-HT 3 receptor antagonist - Google Patents

2,6-methano-2H-quinolizine derivative as a 5-HT 3 receptor antagonist

Info

Publication number
NO943101L
NO943101L NO943101A NO943101A NO943101L NO 943101 L NO943101 L NO 943101L NO 943101 A NO943101 A NO 943101A NO 943101 A NO943101 A NO 943101A NO 943101 L NO943101 L NO 943101L
Authority
NO
Norway
Prior art keywords
treatment
methano
receptor antagonist
quinolizine derivative
hallucinatory
Prior art date
Application number
NO943101A
Other languages
Norwegian (no)
Other versions
NO943101D0 (en
Inventor
Maurice Ward Gittos
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO943101L publication Critical patent/NO943101L/en
Publication of NO943101D0 publication Critical patent/NO943101D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Abstract

Oppfinnelsen angår 5-klor-2,3-dihydro-2,2-dimetylbenzofuran-7-karboksylsyre-oktahydro-3-hydroksy-2,6-metano-2H-kinolizin-8-ylester (I),. en ny 5-HT-reseptorantagonist, dens fremstillingsmetode og dens sluttelige anvendelse ved behandling av radio- og kjemo-terapeutisk-fremkalt kvalme og brekninger, ved behandling av smerte assosiert med migrene, ved behandling av erkjennelsessykdommer, ved behandling av hallusinatoriske, endogene psy-koser av den type som manifesteres i pasienter som lider av schizofreni og mani, for irritabel tarmsyndrom, og for å bekjempe legemiddelmisbruk.The invention relates to 5-chloro-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acid octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester (I). a novel 5-HT receptor antagonist, its method of manufacture and its end use in the treatment of radio- and chemotherapeutic-induced nausea and vomiting, in the treatment of pain associated with migraine, in the treatment of cognitive diseases, in the treatment of hallucinatory, endogenous psychogenic treats of the type manifested in patients suffering from schizophrenia and mania, for irritable bowel syndrome, and to combat drug abuse.

NO943101A 1992-02-24 1994-08-23 2,6-methano-2H-quinolizine derivative as a 5-HT 3 receptor antagonist NO943101D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400474 1992-02-24
PCT/US1993/000880 WO1993017019A1 (en) 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist

Publications (2)

Publication Number Publication Date
NO943101L true NO943101L (en) 1994-08-23
NO943101D0 NO943101D0 (en) 1994-08-23

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943101A NO943101D0 (en) 1992-02-24 1994-08-23 2,6-methano-2H-quinolizine derivative as a 5-HT 3 receptor antagonist

Country Status (14)

Country Link
EP (1) EP0628043A1 (en)
JP (1) JPH07504192A (en)
KR (1) KR100287933B1 (en)
AU (1) AU675060B2 (en)
CA (1) CA2130563C (en)
FI (1) FI105917B (en)
HU (1) HU216831B (en)
IL (1) IL104821A (en)
MX (1) MX9300948A (en)
NO (1) NO943101D0 (en)
NZ (1) NZ249346A (en)
TW (1) TW226374B (en)
WO (1) WO1993017019A1 (en)
ZA (1) ZA931146B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2672500A (en) 1999-02-18 2000-09-04 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (en) 2005-03-07 2009-02-17 Univ Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration.
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68924545T2 (en) * 1988-02-23 1996-03-21 Merrell Dow Pharma Use of quinolizine and quinolizone derivatives for the manufacture of medicaments.
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
EP0628043A1 (en) 1994-12-14
WO1993017019A1 (en) 1993-09-02
AU675060B2 (en) 1997-01-23
FI943872A (en) 1994-08-23
MX9300948A (en) 1993-08-01
CA2130563C (en) 1997-11-11
HU9402436D0 (en) 1994-10-28
CA2130563A1 (en) 1993-09-02
HU216831B (en) 1999-09-28
KR950700297A (en) 1995-01-16
IL104821A0 (en) 1993-06-10
KR100287933B1 (en) 2001-05-02
HUT68249A (en) 1995-06-28
FI105917B (en) 2000-10-31
JPH07504192A (en) 1995-05-11
NZ249346A (en) 1995-10-26
TW226374B (en) 1994-07-11
NO943101D0 (en) 1994-08-23
AU3603493A (en) 1993-09-13
FI943872A0 (en) 1994-08-23
IL104821A (en) 1997-01-10
ZA931146B (en) 1993-09-14

Similar Documents

Publication Publication Date Title
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
TW200505901A (en) Muscarinic agonists
DK0668863T3 (en) Quinuclidine derivative as substance P antagonist
BR0012136A (en) Highly selective norepinephrine reabsorption inhibitors and methods of using them
NO990433L (en) New compounds and compositions for the treatment of diseases associated with tryptase activity
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
EP1007556A4 (en) Troponin subunits and fragments useful as angiogenesis inhibitors
NO20044501L (en) [1,4] diazenino [6,7,1-IJ] quinoline derivatives such as antipsychotics and antidepressants
DK0765320T3 (en) Benzimidazolone derivatives with central dopaminergic activity
DK1276476T3 (en) Use of bradycardic agents in the treatment of cardiovascular diseases associated with hypertrophy, as well as novel drug combinations
FI970469A0 (en) Benzimidazole derivatives with dopaminergic activity
NO943101L (en) 2,6-methano-2H-quinolizine derivative as a 5-HT 3 receptor antagonist
NO991194L (en) Controlled-release dosage form of [R- (Z) - <alfa> - (methoxyimino) - <alfa> - (azabicyclo [2,2,2] oct-3-yl) acetonitrile monohydrochloride
EA200400302A1 (en) METHOD OF TREATING PRIMARY CEREBRESS
BR9911302A (en) Methods to treat bulimia, to treat disorders mediated by vagal activity, to treat irritable bowel syndrome, to treat apnea or apnea disorders, to prevent or control bulimia, disorders mediated by vagal activity, irritable bowel syndrome, bradycardia or bradyarrhythmia, asthma , urinary incontinence, and, apnea or apnea disorders in a patient
NO20005223L (en) Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colon
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
MXPA02006146A (en) Methods for treating psychological disorders using bioactive metabolites of gepirone.
NO984651L (en) Use of benzone-offset derivatives for the manufacture of drugs for the treatment of central nervous system diseases
Glasper et al. Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
NO951865L (en) Quinuclidine derivative as substance P antagonist
Ansseau et al. The use of high dose lormetazepam in psychiatric in-patients
RU2001101163A (en) APPLICATION OF OPTICALLY PURE (+) NORCISAPRID FOR THE TREATMENT OF APNEA, BULIMIA AND OTHER DISORDERS